TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22159931
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg day-1
Study: 17956454
Drug: HOMA‐IR and
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA‐IR and fasting insulin
Study: 11340827
Drug: Preschool speech
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preschool speech and language therapy services
Study: 7920892
Drug: Testosterone or
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone or GnRH treatment
Study: 23174047
Drug: clindamycin 1%/BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin 1%/BPO 5% gel
Study: 23174047
Drug: adapalene 0.1%/BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: adapalene 0.1%/BPO 2.5% gel
Study: 20158589
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% ointment, applied twice weekly for 12 months
Study: 18544020
Drug: tgAAC09 boost
Normalized name: TGAAC09
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tgAAC09 boost dose of 3 x 10(11) DRP
Study: 7537110
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) administered at escalating doses from 0.5 to 10 micrograms/kg/d during chemotherapy cycles 2 to 6.
Study: 7537110
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) administered after chemotherapy.
Study: 7537110
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) administered at escalating doses up to 10 micrograms/kg/d.
Study: 7049582
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (hydrochlorothiazide plus triamterene, with the addition of methyldopa if necessary)
Study: 19127161
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy (corticosteroids, local anesthetics, and other drugs)
Study: 9702843
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (200 mg once daily for 28 days)
Study: 9702843
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (200 mg twice daily for 28 days)
Study: 9702843
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole followed by itraconazole capsules twice daily
Study: 29189517
Drug: Oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone
Study: 16564254
Drug: L-arginine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7.5 g in 500 mL of cardioplegic solution)
Study: 14602763
Drug: TRIAC (19.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIAC (19.6 micro g/kg)
Study: 14602763
Drug: L-T4 (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T4 (1.7 microg/kg)
Study: 20447070
Drug: L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4
Study: 8775350
Drug: Lifestyle education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle education (LSE) - Weekly lifestyle discussions
Study: 6463068
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oxiconazole (one vaginal tablet)
Study: 6463068
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oxiconazole
Study: 6463068
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg econazole
Study: 31905348
Drug: GINA guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: GINA guidelines + FENO modification for ICS titration (group 2)
Study: 28546012
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 mcg.kg−1
Study: 28546012
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 mcg.kg−1
Study: 24530273
Drug: Agomelatine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 10 mg/day (n=133)
Study: 24530273
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg/day (n=138)
Study: 24530273
Drug: Agomelatine 25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25-50 mg/day (n=137)
Study: 26708320
Drug: Agomelatine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 10 mg/day
Study: 24530273
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg and 25-50 mg/day
Study: 24530273
Drug: Agomelatine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (all doses)
Study: 15002600
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment including high caloric intake, Calcium and Vitamin D supplementation
Study: 21669954
Drug: dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 0.1 mg kg(‐1)
Study: 21669954
Drug: dexamethasone 0.05
Normalized name: dexamethasone 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 0.05 mg kg(‐1)
Study: 16906286
Drug: Tomato paste
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato paste (50 g daily for 10 weeks)
Study: 19798465
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (EN) - elemental diet infusion during night-time and a low fat diet during daytime; 32 patients in the EN group.
Study: 19798465
Drug: Non-nutritional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nutritional therapy (non-EN) - no nutritional therapy or food restriction; 24 patients in the non-EN group.
Study: 17622759
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sarpogrelate, orally, three times daily for 7 days
Study: 17622759
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sarpogrelate, orally, three times daily for 7 days
Study: 17622759
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sarpogrelate, orally, three times daily for 7 days
Study: 12177804
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg (n=12)
Study: 12177804
Drug: Anastrozole 10
Normalized name: anastrozole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 10 mg (n=11)
Study: 12177804
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg or 10 mg)
Study: 10205205
Drug: Prucalopride 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 0.5 mg
Study: 25534573
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg
Study: 19035970
Drug: Prucalopride 4
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 4 mg
Study: 10205205
Drug: Prucalopride (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (0.5, 2, and 4 mg doses)
Study: 27804205
Drug: Two mini
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two mini dental implants with Equator attachments
Study: 27804205
Drug: Four mini
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four mini dental implants with Equator attachments
Study: 27804205
Drug: Two conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two conventional dental implants with ball attachments
Study: 29381374
Drug: Hyperglycemia (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (130 mg/dl)
Study: 29381374
Drug: Normoglycemia (95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemia (95 mg/dl)
Study: 29381374
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and leptin levels
Study: 28277490
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 500 U kg‐1 per dose in 2 ml saline intravenously, given on alternate days for a total of five doses
Study: 28277490
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo group), 2 ml given similarly for a total of five doses
Study: 26590242
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose motivational interviewing (10 calls)
Study: 24899321
Drug: 2ml (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml (10 mg) hyperbaric bupivacaine 0.5% plus 25 mg preservative free ketamine
Study: 8864680
Drug: Omeprazole 40mg
Normalized name: OMEPRAZOLE 40MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 40mg once daily for 5 days
Study: 8864680
Drug: Omeprazole 80mg
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80mg once daily for 5 days
Study: 31574029
Drug: Topical Minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Minoxidil
Study: 26705327
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMF) therapy for 12 hours daily for 1 month
Study: 22658168
Drug: Nerve stimulation
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulation guided obturator nerve block with 15 mL of lidocaine HCl 2%
Study: 22658168
Drug: Nerve stimulation
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulation guided obturator nerve block with 20 mL of saline
Study: 29246151
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy
Study: 1519391
Drug: Amoxicillin/Clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/Clavulanic acid (group B)
Study: 10190769
Drug: Ibuprofen (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2400 mg x d(‐1))
Study: 18092435
Drug: Intraumbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraumbilical vein oxytocin (10 units diluted with 10 ml of normal saline)
Study: 11443192
Drug: Pulsatile iv
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile iv GnRH administration (0.1 microg/kg every 90 min)
Study: 8033141
Drug: M‐CSF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐CSF at 100 micrograms/kg/day and gamma‐IFN at 0.1 mg/m2/day
Study: 8033141
Drug: M‐CSF therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐CSF therapy alone at the same dose
Study: 8033141
Drug: M‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐CSF and gamma‐IFN therapy
Study: 29933355
Drug: Caffeine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (800 mg)
Study: 27610609
Drug: Amoxicillin-clavulanate 875
Normalized name: amoxicillin-clavulanate 875 mg-125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 875 mg/125 mg twice daily (BID) for 14 days
Study: 16573163
Drug: Integrin and
Normalized name: DISINTEGRIN AND METALLOPROTEINASE DOMAIN-CONTAINING PROTEIN 11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrin and FAK antibody blocking
Study: 10743865
Drug: 25% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% metronidazole gel
Study: 1598954
Drug: norfloxacin ophthalmic
Normalized name: norfloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin ophthalmic solution 0.3%
Study: 24191305
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (ramipril and telmisartan)
Study: 24191305
Drug: Monotherapy (ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (ramipril or telmisartan)
Study: 22301410
Drug: IL-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 therapy (6 million units, twice daily for 5 days at weeks 0, 8, and 16)
Study: 20618582
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and medication referral as a treatment option
Study: 2566293
Drug: Thymomodulin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymomodulin (80 mg daily orally)
Study: 20825791
Drug: Secobarbital 100
Normalized name: secobarbital 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital 100 mg
Study: 30427741
Drug: V180 formulations
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: V180 formulations with ISCOMATRIX™ adjuvant
Study: 30427741
Drug: Aluminum-adjuvanted formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvanted formulations
Study: 30427741
Drug: Unadjuvanted formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted formulations
Study: 30427741
Drug: All 9
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All 9 V180 formulations
Study: 30427741
Drug: Formulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations with ISCOMATRIX™ adjuvant
Study: 29369527
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DEX and DICL
Study: 27055444
Drug: Long-term interdisciplinary
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term interdisciplinary treatment (LG) - 10 sessions of cognitive behavioral therapy (CBT) and exercise training for 10 weeks.
Study: 27055444
Drug: Short-term interdisciplinary
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term interdisciplinary treatment (SG) - 2 full days of educational, exercise, and CBT programs.
Study: 24739759
Drug: CDX-1401 vaccine
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-1401 vaccine with TLR agonists (resiquimod and Hiltonol)
Study: 24739759
Drug: CDX-1401 vaccine
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-1401 vaccine
Study: 24739759
Drug: CDX-1401 vaccine
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-1401 vaccine followed by immune-checkpoint inhibitors
Study: 19065903
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg per day + NXT 9 tablets per day
Study: 19065903
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg per day
Study: 16317530
Drug: Percutaneous dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous dorsal instrumentation (PER-G)
Study: 16317530
Drug: Open procedure
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open procedure (OP-G)
Study: 1329478
Drug: enalapril 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 5‐20 mg once daily
Study: 29955836
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine
Study: 18822978
Drug: Medication (Madopa)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Madopa)
Study: 12494258
Drug: Seven-valent pneumococcal
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-valent pneumococcal conjugate vaccine (PCV)
Study: 10450448
Drug: High-dose ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ivermectin (up to 1600 micrograms/kg bodyweight)
Study: 10450448
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of ivermectin (150 micrograms/kg bodyweight)
Study: 3130257
Drug: BAYo1248 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAYo1248 (40 mg before breakfast)
Study: 3130257
Drug: BAYm1099 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAYm1099 (100 mg before breakfast and dinner)
Study: 28450388
Drug: Drug-tolerant assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-tolerant assay for detecting anti-drug antibodies (ADAs)
Study: 28450388
Drug: Drug-tolerant assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-tolerant assay after optimization
Study: 28450388
Drug: Drug-tolerant assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-tolerant assay at the end of TAXIT
Study: 27061185
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (control group)
Study: 23743803
Drug: 10-20 mmol
Normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-20 mmol sodium diet and sodium tablets (180 mEq/day)
Study: 7672157
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets
Study: 20426759
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment interruption for > or =96 weeks
Study: 20426759
Drug: Maintained antiretroviral
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintained antiretroviral therapy
Study: 15597104
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg m(‐2))
Study: 15597104
Drug: Docetaxel, irinotecan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel, irinotecan, and lenogastrim (60 mg m(‐2), 200 mg m(‐2), and 150 microg m(‐2) day(‐1), respectively)
Study: 12110110
Drug: Magnesium sulphate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate, 1000 mg intravenously
Study: 12110110
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% physiological saline, 10 ml)
Study: 791605
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg propranolol
Study: 11773918
Drug: Intermediate-dose efegatran
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose efegatran
Study: 11773918
Drug: Efegatran sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efegatran sulfate (high-dose)
Study: 29975272
Drug: ACB alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB alone (15 mL of 0.5% bupivacaine)
Study: 29975272
Drug: ACB+PAI (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB+PAI (15 mL of 0.5% bupivacaine + 50 mL of 0.25% bupivacaine with epinephrine)
Study: 29975272
Drug: PAI alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAI alone (50 mL of 0.25% bupivacaine with epinephrine)
Study: 24496699
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg once daily for 4 weeks, followed by titration to 40 mg for the next 8 weeks.
Study: 24496699
Drug: LCZ696 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 200 mg once daily, titrated to 400 mg, and olmesartan 20 mg, titrated to 40 mg, with possible addition of amlodipine (2.5-5 mg) and hydrochlorothiazide (6.25-25 mg) if BP target not attained.
Study: 25424990
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin daily
Study: 19103535
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin every other day
Study: 10452673
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg twice a day (H2RA)
Study: 10452673
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (PPI)
Study: 10452673
Drug: Daily drinkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily drinkers
Study: 2201825
Drug: Intensive timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive timed sequential treatment using high dose cytarabine
Study: 31324358
Drug: High-dose dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dipyridamole stress echocardiography (0.84 mg/kg)
Study: 23486302
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (WBV) with exercise training
Study: 14579160
Drug: Transforaminal corticosteroid
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal corticosteroid injection
Study: 14579160
Drug: Interspinous corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interspinous corticosteroid injection
Study: 1381218
Drug: granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: granulocyte colony-stimulating factor (G-CSF)
Study: 23702236
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy
Study: 31239114
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical exercise program (1-hour sessions, moderate intensity, twice a week for 12 weeks)
Study: 29090526
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with radiation therapy (RT)